NASDAQ:SGHT Sight Sciences (SGHT) Stock Price, News & Analysis $7.75 -0.28 (-3.49%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.41▼$8.3050-Day Range$5.25▼$8.3152-Week Range$1.04▼$9.31Volume244,296 shsAverage Volume285,838 shsMarket Capitalization$385.64 millionP/E RatioN/ADividend YieldN/APrice Target$5.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Sight Sciences alerts: Email Address Sight Sciences MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside26.5% Downside$5.70 Price TargetShort InterestBearish4.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.31Based on 6 Articles This WeekInsider TradingSelling Shares$290,061 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.13) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.52 out of 5 starsMedical Sector890th out of 936 stocksSurgical & Medical Instruments Industry97th out of 101 stocks 1.0 Analyst's Opinion Consensus RatingSight Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageSight Sciences has only been the subject of 4 research reports in the past 90 days.Read more about Sight Sciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.92% of the float of Sight Sciences has been sold short.Short Interest Ratio / Days to CoverSight Sciences has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Sight Sciences has recently increased by 20.37%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSight Sciences does not currently pay a dividend.Dividend GrowthSight Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SGHT. Previous Next 2.4 News and Social Media Coverage News SentimentSight Sciences has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Sight Sciences this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Sight Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sight Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $290,061.00 in company stock.Percentage Held by Insiders28.90% of the stock of Sight Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Sight Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sight Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sight Sciences are expected to grow in the coming year, from ($1.13) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sight Sciences is -6.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sight Sciences is -6.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSight Sciences has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sight Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.Click here to learn more. About Sight Sciences Stock (NASDAQ:SGHT)Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.Read More SGHT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SGHT Stock News HeadlinesJuly 6, 2024 | insidertrades.comDavid Badawi Sells 3,128 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) StockJuly 4, 2024 | insidertrades.comInsider Selling: Sight Sciences, Inc. (NASDAQ:SGHT) COO Sells 3,525 Shares of StockJuly 27, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.July 25 at 9:33 PM | bizjournals.comC-Suite Awards 2024: Ingrid Schunder of Miracles in SightJuly 22, 2024 | americanbankingnews.comSight Sciences, Inc. (NASDAQ:SGHT) Receives $5.70 Average Price Target from BrokeragesJuly 20, 2024 | msn.comStudy finds people who lost sight early in life are less accurate at estimating auditory distancesJuly 18, 2024 | globenewswire.comSight Sciences to Report Second Quarter Financial Results on August 1, 2024June 10, 2024 | globenewswire.comSight Sciences Announces the Release of its First Sustainability ReportJuly 27, 2024 | Weiss Ratings (Ad)The next companies to potentially benefit thanks to Nvidia are …Nvidia is pivoting to a new $1 trillion Superproject that could revolutionize the AI industry… again. And it’s enlisting a whole new set of partners.May 29, 2024 | msn.comWhat is the true story behind ‘Sight’? Movie details life of immigrant and surgeon Dr. Ming WangMay 28, 2024 | msn.comSight Care Scam Exposed (User And Expert Opinions) Can You Expect Real Results Or Unproven Claims?May 28, 2024 | globenewswire.comSight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from RestasisMay 28, 2024 | globenewswire.comSight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced GlaucomaMay 25, 2024 | latimes.com‘Sight’ highlights the journey and faith of an Asian American medical hero who helped the blind seeMay 6, 2024 | finance.yahoo.comSight Sciences, Inc. (NASDAQ:SGHT) Q1 2024 Earnings Call TranscriptMay 4, 2024 | finance.yahoo.comSight Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 3, 2024 | finance.yahoo.comQ1 2024 Sight Sciences Inc Earnings CallMay 2, 2024 | investorplace.comSGHT Stock Earnings: Sight Sciences Misses EPS, Beats Revenue for Q1 2024See More Headlines Receive SGHT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sight Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today7/27/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:SGHT CUSIPN/A CIK1531177 Webwww.sightsciences.com Phone877-266-1144FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$5.70 High Stock Price Target$6.50 Low Stock Price Target$4.50 Potential Upside/Downside-26.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-55,550,000.00 Net Margins-67.18% Pretax Margin-67.04% Return on Equity-44.45% Return on Assets-32.01% Debt Debt-to-Equity Ratio0.31 Current Ratio13.01 Quick Ratio12.42 Sales & Book Value Annual Sales$81.06 million Price / Sales4.76 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book3.14Miscellaneous Outstanding Shares49,760,000Free Float35,377,000Market Cap$385.64 million OptionableOptionable Beta2.74 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Paul Badawi (Age 49)Co-Founder, President, CEO & Director Comp: $920.3kDr. David Badawi M.D. (Age 54)Founder, CTO & Director Mr. Sam Boong Park (Age 63)Chief Operating Officer Comp: $531.78kMs. Alison Perry Bauerlein (Age 43)CFO & Treasurer Mr. Jeremy B. Hayden (Age 54)Chief Legal Officer Mr. Steve R. Tamayo Jr.VP and Chief Ethics & Compliance OfficerDr. Reay H. BrownChief Medical OfficerTom HuangHead of Corporate Strategy & DevelopmentMr. Matthew W. Link (Age 49)Chief Commercial Officer Mr. Stephen B. Thau J.D.SecretaryMore ExecutivesKey CompetitorsSurmodicsNASDAQ:SRDXBioventusNYSE:BVSOrthofix MedicalNASDAQ:OFIXAerie PharmaceuticalsNASDAQ:AERISmileDirectClubNASDAQ:SDCView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 42,383 shares on 7/26/2024Ownership: 0.206%Steele Capital Management Inc.Bought 10,000 shares on 7/16/2024Ownership: 0.020%Alison BauerleinSold 10,497 sharesTotal: $65,186.37 ($6.21/share)Sam Boong ParkSold 3,525 sharesTotal: $21,890.25 ($6.21/share)Jeremy B HaydenSold 5,055 sharesTotal: $31,391.55 ($6.21/share)View All Insider TransactionsView All Institutional Transactions SGHT Stock Analysis - Frequently Asked Questions How have SGHT shares performed this year? Sight Sciences' stock was trading at $5.16 at the start of the year. Since then, SGHT stock has increased by 50.2% and is now trading at $7.75. View the best growth stocks for 2024 here. How were Sight Sciences' earnings last quarter? Sight Sciences, Inc. (NASDAQ:SGHT) issued its earnings results on Thursday, May, 2nd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.04. The firm earned $19.27 million during the quarter, compared to analyst estimates of $18.34 million. Sight Sciences had a negative net margin of 67.18% and a negative trailing twelve-month return on equity of 44.45%. When did Sight Sciences IPO? Sight Sciences (SGHT) raised $150 million in an IPO on Thursday, July 15th 2021. The company issued 6,980,000 shares at $20.00-$23.00 per share. Who are Sight Sciences' major shareholders? Top institutional shareholders of Sight Sciences include Bank of New York Mellon Corp (0.21%) and Steele Capital Management Inc. (0.02%). Insiders that own company stock include Paul Badawi, D1 Capital Partners LP, David Badawi, Staffan Encrantz, Sam Boong Park, Jeremy B Hayden and Jesse Selnick. View institutional ownership trends. How do I buy shares of Sight Sciences? Shares of SGHT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SGHT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sight Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sight Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
